<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN">
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=UTF-8">
    <title>Description of interventions_7</title>
    <link href="data:image/x-icon;base64,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" rel="icon" type="image/x-icon">
    <style>@import "https://fonts.googleapis.com/css?family=Source+Sans+Pro:ital,wgth:0,400;0,700;1,400;1,700";body {  font-family: "Source Sans Pro", sans-serif;  margin: 40px;}@media screen {  #backToTop {    position: fixed;    bottom: 0px;    left: 50%;    transform: translateX(-50%);    border-radius: 4px 4px 0 0;    padding: 4px 12px 4px 12px;    background: #1f3c73;    font-weight: bold;  }  #backToTop a {    color: white;  }}@media print {  #backToTop {    display: none;  }}table {  width: fit-content;  border-collapse: collapse;}th {  font-weight: bold;  background: LightGray;}td, th {  border: 1px solid LightGray;  padding: 8px;  font-size: 14px;  vertical-align: top;}caption {  font-weight: bold;  font-size: large;  text-align: left;  padding: 8px;}h1 {  font-size:38.5px;}h2 {  font-size:31.5px;}h1 small, h3 {  font-size:24.5px;}h2 small, h4 {  font-size:17.5px;}h3 small, h4 small, h5 {  font-size:14px;}h6 {  font-size:11.9px;}a {  color: #002d64;  text-decoration: none;}.byline {  font-weight: bold;  color: #002D64;}.disclaimer {  font-style: italic;}figure, table.analysis {  width: fit-content;  display: block;  margin-block-start: 1em;  margin-block-end: 1em;  margin-inline-start: 40px;  margin-inline-end: 40px;}thead tr td, th, figcaption, caption {  font-weight: bold;  background: LightGray;}span.inserted {  background-color: #e5ffcd;}span.deleted {  background-color: #e5ffcd;  text-decoration: line-through;}span.marker-yellow {  background-color: #ffff80;}ol ol {  list-style-type: lower-alpha;}ol ol ol {  list-style-type: lower-roman;}</style>
  </head>
  <body>
    <div class="logo">
      <svg xmlns="http://www.w3.org/2000/svg" height="57" viewBox="0 0 1138.5 192" width="338" xml:space="preserve">
        <path d="M86 .5v33a63.3 63.3 0 0 0 0 125v33a96 96 0 0 1 0-191zM106 .5v33a63.3 63.3 0 0 1 0 125v33a96 96 0 0 0 0-191z" fill="#1f3c73"></path>
        <path d="M93 0h6v192h-6z" fill="#a53995"></path>
        <path d="M93 0h6v192h-6zM82 44h8v6h-8z" fill="#a53995"></path>
        <path d="M63 58h40v6H63zM69 73h30v6H69zM78 86h36v6H78zM63 100h42v6H63zM60 114h28v6H60zM88 128h15v6H88zM84 140l6 6-6 6-6-6z" fill="#a53995"></path>
        <g aria-label="Cochrane" fill="#1f3c73" stroke-width="3.368">
          <path d="M256.96 82.722q-7.366 0-13.564-3.413-6.198-3.414-9.97-10.06-3.683-6.737-3.683-16.528 0-9.701 3.772-16.528 3.863-6.917 10.15-10.51 6.378-3.682 13.743-3.682 5.66 0 10.15 2.335 4.492 2.246 7.456 5.3l-7.007 8.443q-2.245-2.066-4.76-3.323-2.426-1.347-5.57-1.347-3.952 0-7.275 2.245-3.234 2.246-5.21 6.468-1.886 4.221-1.886 10.15 0 8.982 3.862 14.013 3.863 5.03 10.33 5.03 3.593 0 6.378-1.617 2.874-1.617 5.03-3.863l7.006 8.264q-7.365 8.624-18.953 8.624zM302.86 82.722q-5.659 0-10.689-2.695-4.94-2.784-7.994-7.994-3.054-5.3-3.054-12.665 0-7.456 3.054-12.665 3.054-5.21 7.994-7.905 5.03-2.784 10.689-2.784t10.599 2.784q4.94 2.695 7.994 7.905 3.054 5.21 3.054 12.665 0 7.365-3.054 12.665-3.054 5.21-7.994 7.994-4.94 2.695-10.599 2.695zm0-10.689q4.042 0 6.108-3.413 2.066-3.504 2.066-9.252 0-5.839-2.066-9.252-2.066-3.413-6.108-3.413-4.132 0-6.198 3.413-1.976 3.413-1.976 9.252 0 5.749 1.976 9.252 2.066 3.413 6.198 3.413zM352.98 82.722q-6.198 0-11.228-2.695-4.94-2.784-7.905-7.994-2.874-5.3-2.874-12.665 0-7.456 3.234-12.665 3.233-5.21 8.533-7.905 5.3-2.784 11.408-2.784 4.132 0 7.276 1.347 3.234 1.348 5.749 3.413l-6.198 8.534q-3.144-2.605-6.018-2.605-4.761 0-7.636 3.413-2.784 3.413-2.784 9.252 0 5.749 2.784 9.252 2.875 3.413 7.186 3.413 2.156 0 4.222-.898 2.066-.988 3.773-2.335l5.21 8.623q-3.324 2.874-7.186 4.132-3.863 1.167-7.546 1.167zM375.53 81.644V18.677h13.204v15.45l-.629 7.994q2.515-2.245 5.839-4.131 3.413-1.977 7.904-1.977 7.276 0 10.51 4.85 3.323 4.762 3.323 13.115v27.666h-13.204v-25.96q0-4.85-1.347-6.646-1.258-1.797-4.132-1.797-2.515 0-4.312 1.168-1.796 1.078-3.952 3.144v30.091zM426.82 81.644V37.091h10.779l.898 7.815h.36q2.425-4.491 5.838-6.647 3.413-2.246 6.827-2.246 1.886 0 3.144.27 1.257.18 2.156.628l-2.156 11.408q-1.168-.359-2.336-.539-1.078-.18-2.515-.18-2.515 0-5.3 1.887-2.694 1.797-4.49 6.288v25.869zM471.28 82.722q-6.108 0-9.701-3.862-3.593-3.953-3.593-9.612 0-7.006 5.928-10.959 5.929-3.952 19.133-5.3-.18-2.964-1.796-4.67-1.527-1.797-5.21-1.797-2.785 0-5.659 1.078-2.874 1.078-6.108 2.964l-4.76-8.713q4.221-2.605 8.982-4.222 4.85-1.616 10.06-1.616 8.533 0 13.114 4.94 4.58 4.94 4.58 15.18v25.51h-10.778l-.898-4.581h-.36q-2.784 2.515-6.018 4.132-3.144 1.527-6.916 1.527zm4.491-10.24q2.246 0 3.863-.988 1.706-1.078 3.413-2.785v-7.814q-7.006.898-9.701 2.874-2.695 1.886-2.695 4.491 0 2.156 1.348 3.234 1.437.988 3.772.988zM507.39 81.644V37.091h10.779l.898 5.659h.36q2.874-2.695 6.287-4.671 3.503-2.066 7.995-2.066 7.275 0 10.509 4.85 3.323 4.761 3.323 13.115v27.666h-13.204v-25.96q0-4.85-1.347-6.646-1.258-1.797-4.132-1.797-2.515 0-4.312 1.168-1.796 1.078-3.952 3.144v30.09zM578.71 82.722q-6.378 0-11.498-2.785-5.12-2.784-8.084-7.994-2.964-5.21-2.964-12.575 0-7.276 2.964-12.486 3.054-5.21 7.904-7.994 4.85-2.875 10.15-2.875 6.378 0 10.51 2.875 4.221 2.784 6.287 7.635 2.156 4.76 2.156 10.869 0 1.706-.18 3.413-.18 1.617-.36 2.425h-26.677q.898 4.85 4.042 7.186 3.144 2.246 7.545 2.246 4.761 0 9.612-2.964l4.4 7.994q-3.412 2.335-7.634 3.683-4.222 1.347-8.174 1.347zm-9.88-28.205h16.078q0-3.683-1.796-6.018-1.707-2.426-5.66-2.426-3.053 0-5.479 2.156-2.425 2.066-3.143 6.288z"></path>
        </g>
        <g aria-label="Library" fill="#a53995" stroke-width="3.368">
          <path d="M236.48 168.68v-58.925h7.455v52.547h25.78v6.378zM279.42 168.68v-43.655h7.366v43.655zm3.773-52.637q-2.156 0-3.593-1.258-1.348-1.347-1.348-3.593 0-2.155 1.348-3.503 1.437-1.347 3.593-1.347 2.155 0 3.503 1.347 1.437 1.348 1.437 3.503 0 2.246-1.437 3.593-1.348 1.258-3.503 1.258zM320.82 169.76q-3.054 0-6.378-1.437-3.233-1.527-6.108-4.132h-.27l-.628 4.491h-5.928v-63.955h7.365v17.426l-.18 7.905q2.965-2.605 6.468-4.312 3.593-1.796 7.186-1.796 8.533 0 12.935 6.018 4.401 6.018 4.401 16.168 0 7.455-2.694 12.755-2.605 5.3-6.917 8.084-4.222 2.785-9.252 2.785zm-1.258-6.198q5.39 0 8.893-4.58 3.593-4.672 3.593-12.756 0-7.186-2.695-11.587-2.605-4.491-8.803-4.491-2.784 0-5.659 1.527-2.874 1.527-6.018 4.401v22.905q2.875 2.515 5.66 3.593 2.874.988 5.03.988zM351.19 168.68v-43.655h6.108l.629 7.905h.27q2.245-4.132 5.479-6.558 3.233-2.425 6.916-2.425 2.605 0 4.671.898l-1.437 6.468q-1.078-.36-1.976-.54-.899-.179-2.246-.179-2.784 0-5.838 2.246-2.965 2.245-5.21 7.814v28.025zM390.26 169.76q-5.48 0-9.162-3.234-3.593-3.323-3.593-9.162 0-7.186 6.377-10.959 6.468-3.862 20.39-5.39 0-2.784-.808-5.299-.719-2.515-2.695-4.042-1.886-1.617-5.479-1.617-3.773 0-7.096 1.437-3.324 1.438-5.928 3.234l-2.875-5.12q3.054-1.976 7.456-3.773 4.49-1.886 9.7-1.886 7.995 0 11.588 4.94 3.593 4.851 3.593 13.026v26.768h-6.108l-.63-5.21h-.269q-3.054 2.515-6.736 4.401-3.593 1.886-7.725 1.886zm2.156-5.928q3.144 0 5.928-1.527 2.785-1.527 5.929-4.312v-12.126q-10.87 1.347-15.27 4.042-4.312 2.695-4.312 6.917 0 3.682 2.246 5.39 2.245 1.616 5.479 1.616zM425.47 168.68v-43.655h6.108l.629 7.905h.27q2.245-4.132 5.479-6.558 3.233-2.425 6.916-2.425 2.605 0 4.671.898l-1.437 6.468q-1.078-.36-1.976-.54-.898-.179-2.246-.179-2.784 0-5.838 2.246-2.965 2.245-5.21 7.814v28.025zM459.6 187.45q-1.437 0-2.785-.27-1.257-.269-2.335-.628l1.437-5.839q.719.18 1.617.36.898.269 1.707.269 3.683 0 6.108-2.695 2.425-2.605 3.772-6.647l.988-3.233-17.516-43.745h7.636l8.892 24.163q.988 2.784 2.066 6.018 1.168 3.233 2.156 6.287h.36q.987-2.964 1.886-6.197.898-3.234 1.796-6.109l7.815-24.163h7.186l-16.438 47.248q-1.527 4.312-3.683 7.725-2.066 3.414-5.21 5.39-3.054 2.066-7.455 2.066z"></path>
        </g>
        <g aria-label="Trusted evidence." fill="#1f3c73" stroke-width="3.368">
          <path d="M710.25 61.723V30.141h-10.671v-3.773h25.869v3.773h-10.671v31.582zM728.9 61.723V35.53h3.665l.377 4.743h.162q1.347-2.48 3.287-3.935t4.15-1.455q1.563 0 2.803.54l-.863 3.88q-.646-.216-1.185-.324-.54-.108-1.348-.108-1.67 0-3.503 1.348-1.778 1.347-3.126 4.689v16.815zM755.25 62.37q-4.15 0-6.09-2.587-1.94-2.64-1.94-7.653v-16.6h4.473v16.007q0 3.665 1.132 5.336 1.185 1.67 3.772 1.67 2.048 0 3.611-1.024 1.617-1.078 3.45-3.395V35.53h4.42v26.193h-3.666l-.377-4.096h-.162q-1.832 2.156-3.88 3.45-2.048 1.293-4.743 1.293zM783.76 62.37q-2.803 0-5.336-1.024-2.533-1.078-4.419-2.587l2.21-2.964q1.724 1.347 3.557 2.263 1.832.863 4.15.863 2.587 0 3.88-1.186 1.294-1.24 1.294-2.91 0-1.348-.917-2.264-.862-.916-2.263-1.509-1.348-.647-2.803-1.186-1.832-.7-3.61-1.562-1.78-.917-2.911-2.318-1.132-1.455-1.132-3.665 0-3.18 2.372-5.281 2.425-2.156 6.683-2.156 2.425 0 4.527.862t3.61 2.102l-2.155 2.802q-1.347-1.024-2.803-1.67-1.455-.647-3.18-.647-2.479 0-3.664 1.132-1.132 1.132-1.132 2.64 0 1.24.809 2.049.808.754 2.101 1.347 1.294.539 2.749 1.132 1.886.7 3.719 1.617 1.832.862 3.018 2.371 1.24 1.455 1.24 3.934 0 2.102-1.132 3.88-1.078 1.78-3.234 2.857-2.102 1.078-5.228 1.078zM806.67 62.37q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306V39.141h-3.88V35.8l4.095-.27.54-7.33h3.718v7.33h7.06v3.61h-7.06v14.553q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.509-.216l1.455-.485.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM826.5 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.071-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.562 2.91q-1.67 1.078-3.826 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM851.56 62.37q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V23.35h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61V41.35q-1.67-1.509-3.234-2.102-1.509-.646-3.126-.646-2.101 0-3.826 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.69 1.886 7.384 1.887 2.64 5.336 2.64zM893.92 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743t-1.67-7.33q0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.706 3.341 2.75 3.342 2.75 8.947 0 .7-.055 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.796.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.959 2.156-2.155 2.102-2.587 5.982zM915.97 61.723l-9.432-26.193h4.581l4.959 14.875 1.185 3.88q.647 1.94 1.24 3.827h.216q.592-1.886 1.185-3.827.647-1.94 1.186-3.88l4.958-14.875h4.366l-9.27 26.193zM935.48 61.723V35.53h4.42v26.193zm2.264-31.582q-1.294 0-2.156-.755-.809-.808-.809-2.155 0-1.294.809-2.102.862-.809 2.156-.809 1.293 0 2.101.809.863.808.863 2.102 0 1.347-.862 2.155-.809.755-2.102.755zM957.68 62.37q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V23.35h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61V41.35q-1.67-1.509-3.234-2.102-1.509-.646-3.126-.646-2.101 0-3.826 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.69 1.887 7.384 1.886 2.64 5.335 2.64zM989.26 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743t-1.67-7.33q0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM1005.4 61.723V35.53h3.665l.377 3.773h.162q1.886-1.887 3.988-3.126 2.102-1.294 4.797-1.294 4.15 0 6.036 2.641 1.94 2.587 1.94 7.6v16.6h-4.42V45.715q0-3.665-1.185-5.335t-3.773-1.671q-1.994 0-3.61 1.024-1.563 1.024-3.558 3.018v18.971zM1045.2 62.37q-3.45 0-6.252-1.617t-4.42-4.689q-1.616-3.072-1.616-7.383 0-4.42 1.725-7.492 1.778-3.072 4.635-4.688 2.91-1.617 6.251-1.617 2.587 0 4.42.916 1.886.916 3.233 2.156l-2.263 2.91q-1.132-1.024-2.425-1.67-1.24-.647-2.803-.647-2.371 0-4.258 1.293-1.832 1.24-2.91 3.557-1.024 2.264-1.024 5.282 0 4.473 2.21 7.276 2.263 2.748 5.874 2.748 1.833 0 3.396-.754 1.563-.809 2.748-1.887l1.94 2.965q-1.778 1.563-3.934 2.479-2.156.862-4.527.862zM1068.9 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.071-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.707 3.341 2.748 3.342 2.748 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.678q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.724-6.036-1.671-2.102-4.743-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM1087.4 62.37q-1.347 0-2.317-.916-.917-.97-.917-2.426 0-1.562.917-2.479.97-.97 2.317-.97 1.294 0 2.21.97.97.916.97 2.48 0 1.455-.97 2.425-.916.916-2.21.916z"></path>
        </g>
        <g aria-label="Informed decisions." fill="#1f3c73" stroke-width="3.368">
          <path d="M699.58 124.7V89.345h4.473V124.7zM713.32 124.7V98.507h3.665l.377 3.773h.162q1.886-1.887 3.988-3.126 2.102-1.294 4.797-1.294 4.15 0 6.036 2.641 1.94 2.587 1.94 7.6v16.6h-4.42v-16.008q0-3.665-1.185-5.335-1.186-1.671-3.773-1.671-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018V124.7zM743.56 124.7v-22.582h-3.557v-3.341l3.557-.27v-4.15q0-3.988 1.832-6.306 1.887-2.371 5.821-2.371 1.24 0 2.371.27 1.132.215 1.995.592l-.97 3.396q-1.456-.647-2.965-.647-3.665 0-3.665 5.066v4.15h5.552v3.61h-5.552V124.7zM768.19 125.35q-3.18 0-5.982-1.617-2.749-1.617-4.474-4.689-1.67-3.072-1.67-7.383 0-4.42 1.67-7.492 1.725-3.072 4.474-4.688 2.802-1.617 5.982-1.617 3.234 0 5.982 1.617 2.749 1.616 4.42 4.688 1.724 3.072 1.724 7.492 0 4.311-1.724 7.383-1.671 3.072-4.42 4.69t-5.982 1.616zm0-3.665q3.395 0 5.443-2.748 2.102-2.803 2.102-7.276 0-4.527-2.102-7.33-2.048-2.802-5.443-2.802-3.341 0-5.443 2.802t-2.102 7.33q0 4.473 2.102 7.276 2.102 2.748 5.443 2.748zM787.21 124.7V98.507h3.665l.377 4.743h.162q1.347-2.48 3.287-3.935t4.15-1.455q1.563 0 2.803.54l-.863 3.88q-.646-.216-1.185-.324-.54-.108-1.348-.108-1.67 0-3.503 1.348-1.778 1.347-3.126 4.689V124.7zM805.91 124.7V98.507h3.665l.377 3.773h.162q1.724-1.887 3.772-3.126 2.048-1.294 4.366-1.294 3.018 0 4.689 1.348 1.724 1.293 2.533 3.664 2.048-2.21 4.15-3.61 2.101-1.402 4.473-1.402 4.042 0 5.982 2.641 1.994 2.587 1.994 7.6v16.6h-4.42v-16.008q0-3.665-1.185-5.335-1.186-1.671-3.665-1.671-2.91 0-6.575 4.042V124.7h-4.42v-16.007q0-3.665-1.185-5.336-1.186-1.67-3.719-1.67-2.91 0-6.575 4.042v18.97zM861.21 125.35q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.071-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.562 2.91q-1.67 1.078-3.826 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.724-6.036-1.671-2.102-4.743-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM886.27 125.35q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V86.33h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61v-13.69q-1.67-1.509-3.234-2.102-1.509-.646-3.126-.646-2.101 0-3.826 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.689 1.886 7.384 1.887 2.64 5.336 2.64zM926.96 125.35q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V86.33h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61v-13.69q-1.67-1.509-3.234-2.102-1.509-.646-3.125-.646-2.102 0-3.827 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.689 1.887 7.384 1.886 2.64 5.335 2.64zM958.54 125.35q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743t-1.67-7.33q0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.959 2.156-2.155 2.102-2.587 5.982zM985.01 125.35q-3.45 0-6.252-1.617-2.802-1.617-4.42-4.689-1.616-3.072-1.616-7.383 0-4.42 1.725-7.492 1.778-3.072 4.635-4.688 2.91-1.617 6.251-1.617 2.587 0 4.42.916 1.886.916 3.233 2.156l-2.263 2.91q-1.132-1.024-2.425-1.67-1.24-.647-2.803-.647-2.371 0-4.258 1.293-1.832 1.24-2.91 3.557-1.024 2.264-1.024 5.282 0 4.473 2.21 7.276 2.263 2.748 5.874 2.748 1.833 0 3.396-.754 1.563-.809 2.748-1.887l1.94 2.965q-1.778 1.563-3.934 2.479-2.156.862-4.527.862zM999.23 124.7V98.507h4.42V124.7zm2.264-31.582q-1.294 0-2.156-.755-.809-.808-.809-2.155 0-1.294.809-2.102.862-.809 2.156-.809 1.293 0 2.101.809.863.808.863 2.102 0 1.347-.862 2.155-.809.755-2.102.755zM1019.3 125.35q-2.803 0-5.336-1.024-2.533-1.078-4.419-2.587l2.21-2.964q1.724 1.347 3.557 2.263 1.832.863 4.15.863 2.587 0 3.88-1.186 1.293-1.24 1.293-2.91 0-1.348-.916-2.264-.862-.916-2.263-1.509-1.348-.647-2.803-1.185-1.832-.701-3.61-1.563-1.78-.917-2.911-2.318-1.132-1.455-1.132-3.665 0-3.18 2.371-5.281 2.426-2.156 6.683-2.156 2.426 0 4.528.862 2.101.862 3.61 2.102l-2.155 2.803q-1.348-1.024-2.803-1.671-1.455-.647-3.18-.647-2.479 0-3.664 1.132-1.132 1.132-1.132 2.64 0 1.24.808 2.049.809.754 2.102 1.347 1.294.539 2.749 1.132 1.886.7 3.718 1.617 1.833.862 3.019 2.371 1.24 1.455 1.24 3.934 0 2.102-1.133 3.88-1.078 1.78-3.233 2.857-2.102 1.078-5.228 1.078zM1035.1 124.7V98.507h4.42V124.7zm2.264-31.582q-1.294 0-2.156-.755-.809-.808-.809-2.155 0-1.294.809-2.102.862-.809 2.156-.809t2.101.809q.863.808.863 2.102 0 1.347-.863 2.155-.808.755-2.101.755zM1058.5 125.35q-3.18 0-5.982-1.617-2.749-1.617-4.474-4.689-1.67-3.072-1.67-7.383 0-4.42 1.67-7.492 1.725-3.072 4.474-4.688 2.802-1.617 5.982-1.617 3.234 0 5.982 1.617 2.749 1.616 4.42 4.688 1.724 3.072 1.724 7.492 0 4.311-1.724 7.383-1.671 3.072-4.42 4.69-2.748 1.616-5.982 1.616zm0-3.665q3.395 0 5.443-2.748 2.102-2.803 2.102-7.276 0-4.527-2.102-7.33-2.048-2.802-5.443-2.802-3.341 0-5.443 2.802t-2.102 7.33q0 4.473 2.102 7.276 2.101 2.748 5.443 2.748zM1077.5 124.7V98.507h3.665l.377 3.773h.162q1.886-1.887 3.988-3.126 2.102-1.294 4.797-1.294 4.15 0 6.036 2.641 1.94 2.587 1.94 7.6v16.6h-4.42v-16.008q0-3.665-1.185-5.335-1.186-1.671-3.773-1.671-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018V124.7zM1113.9 125.35q-2.803 0-5.336-1.024-2.533-1.078-4.419-2.587l2.21-2.964q1.724 1.347 3.557 2.263 1.832.863 4.15.863 2.587 0 3.88-1.186 1.293-1.24 1.293-2.91 0-1.348-.916-2.264-.862-.916-2.263-1.509-1.348-.647-2.803-1.185-1.832-.701-3.61-1.563-1.78-.917-2.911-2.318-1.132-1.455-1.132-3.665 0-3.18 2.372-5.281 2.425-2.156 6.683-2.156 2.425 0 4.527.862 2.102.862 3.61 2.102l-2.155 2.803q-1.348-1.024-2.803-1.671-1.455-.647-3.18-.647-2.479 0-3.664 1.132-1.132 1.132-1.132 2.64 0 1.24.808 2.049.809.754 2.102 1.347 1.294.539 2.749 1.132 1.886.7 3.718 1.617 1.833.862 3.019 2.371 1.24 1.455 1.24 3.934 0 2.102-1.133 3.88-1.078 1.78-3.233 2.857-2.102 1.078-5.228 1.078zM1131.9 125.35q-1.347 0-2.317-.916-.917-.97-.917-2.426 0-1.562.917-2.479.97-.97 2.317-.97 1.294 0 2.21.97.97.916.97 2.48 0 1.455-.97 2.425-.916.916-2.21.916z"></path>
        </g>
        <g aria-label="Better health." fill="#a53995" stroke-width="3.368">
          <path d="M699.58 187.95v-35.355h10.509q3.61 0 6.306.862 2.748.863 4.257 2.749 1.563 1.886 1.563 5.012 0 2.64-1.347 4.797-1.294 2.102-3.827 2.91v.216q3.18.592 5.174 2.694 2.048 2.102 2.048 5.767 0 3.45-1.724 5.767-1.671 2.317-4.69 3.449-3.017 1.132-7.005 1.132zm4.473-20.318h5.228q4.527 0 6.521-1.563 1.994-1.563 1.994-4.258 0-3.072-2.101-4.365-2.048-1.294-6.198-1.294h-5.444zm0 16.761h6.144q4.581 0 7.114-1.67 2.533-1.725 2.533-5.282 0-3.288-2.533-4.797-2.479-1.563-7.114-1.563h-6.144zM741.46 188.6q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.072-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.706 3.341 2.75 3.342 2.75 8.947 0 .7-.055 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.796.808zm-8.246-15.845h14.013q0-3.988-1.724-6.036-1.671-2.102-4.743-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM765.28 188.6q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306v-14.498h-3.88v-3.341l4.095-.27.54-7.33h3.718v7.33h7.06v3.611h-7.06v14.552q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.51-.215l1.454-.486.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM782.42 188.6q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306v-14.498h-3.88v-3.341l4.095-.27.54-7.33h3.718v7.33h7.06v3.611h-7.06v14.552q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.51-.215l1.454-.486.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM802.25 188.6q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.072-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.562 2.91q-1.67 1.078-3.826 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM818.36 187.95v-26.193h3.665l.377 4.743h.162q1.347-2.48 3.287-3.935t4.15-1.455q1.563 0 2.803.54l-.863 3.88q-.646-.216-1.185-.324t-1.348-.108q-1.67 0-3.503 1.348-1.778 1.347-3.126 4.689v16.815zM847.84 187.95v-38.373h4.42v10.456l-.162 5.39q1.886-1.779 3.934-3.019 2.102-1.293 4.797-1.293 4.15 0 6.036 2.64 1.94 2.588 1.94 7.6v16.6h-4.42v-16.007q0-3.665-1.185-5.336-1.186-1.67-3.773-1.67-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018v18.97zM887.78 188.6q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.072-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.706 3.341 2.75 3.342 2.75 8.947 0 .7-.055 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.796.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.959 2.156-2.155 2.102-2.586 5.982zM909.18 188.6q-3.288 0-5.497-1.94-2.156-1.994-2.156-5.498 0-4.311 3.826-6.575 3.88-2.317 12.234-3.233 0-1.671-.485-3.18-.43-1.51-1.616-2.426-1.132-.97-3.288-.97-2.264 0-4.258.863-1.994.862-3.557 1.94l-1.724-3.072q1.832-1.186 4.473-2.264 2.695-1.131 5.82-1.131 4.797 0 6.953 2.964 2.156 2.91 2.156 7.814v16.061h-3.665l-.377-3.125h-.162q-1.832 1.509-4.042 2.64-2.156 1.132-4.635 1.132zm1.294-3.557q1.886 0 3.556-.916 1.671-.916 3.557-2.587v-7.276q-6.52.808-9.162 2.425-2.587 1.617-2.587 4.15 0 2.21 1.348 3.234 1.347.97 3.287.97zM934.99 188.6q-2.48 0-3.61-1.509-1.079-1.563-1.079-4.42v-33.09h4.42v33.415q0 1.024.377 1.509.377.43.862.43h.377q.216-.053.593-.107l.593 3.341q-.431.216-1.024.324-.593.108-1.509.108zM952.29 188.6q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306v-14.498h-3.88v-3.341l4.095-.27.54-7.33h3.718v7.33h7.06v3.611h-7.06v14.552q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.51-.215l1.454-.486.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM962.26 187.95v-38.373h4.42v10.456l-.162 5.39q1.886-1.779 3.934-3.019 2.102-1.293 4.797-1.293 4.15 0 6.036 2.64 1.94 2.588 1.94 7.6v16.6h-4.42v-16.007q0-3.665-1.185-5.336-1.186-1.67-3.773-1.67-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018v18.97zM993.9 188.6q-1.347 0-2.317-.916-.917-.97-.917-2.426 0-1.563.916-2.479.97-.97 2.318-.97 1.294 0 2.21.97.97.917.97 2.48 0 1.455-.97 2.425-.917.916-2.21.916z"></path>
        </g>
      </svg>
    </div>
    <h1>Supplementary material 31 to: Daily iron supplementation for prevention or treatment of iron deficiency anaemia in infants, children, and adolescents</h1>
    <p>
      <span class="byline">Rajagopalan K, Hackl L, Pe&ntilde;a-Rosas JP, Garcia-Casal MN, Rizal M, Mehta NH, Roudik M, Islam S, Trumbull-Kennedy MM, Khondakar NR, Franco JVA, Finkelstein JL, Mehta S</span>
      <br>
      <span class="doi"><a href="https://doi.org/10.1002/14651858.CD013227.pub2">https://doi.org/10.1002/14651858.CD013227.pub2</a></span>
    </p>
    <p>
      <span class="disclaimer">The material in this section has been supplied by the author(s) for publication under a Licence for Publication and the author(s) are solely responsible for the material. Cochrane has reviewed this material, but Cochrane has not copyedited, formatted or proofread. Cochrane accordingly gives no representations or warranties of any kind in relation to, and accepts no liability for any reliance on or use of, such material.</span>
    </p>
    <div id="backToTop">
      <a href="#top">Back to top</a>
    </div>
    <h1>Description of interventions_7</h1>
    <div>
      <table>
        <tr>
          <th style="vertical-align: top;">
            <p>Item</p>
          </th><th style="vertical-align: top;">
            <p>Study ID</p>
          </th>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Sungthong 2002</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>"Once weekly is superior to daily iron supplementation on height gain but not on hematological improvement among schoolchildren in Thailand" and "differentially affect cognitive function but not school performance"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"...primary schoolchildren, aged ranging from 6 to 13 y"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"In Thailand...a once daily iron supplementation program has been carried out among anemic children since 1988, and a once weekly dose administered through a school-based program among primary schoolchildren will soon be implemented. It is essential to conduct a randomized controlled trial to assess the efficacy of once weekly iron supplementation before the large-scale program is launched. The main objective of this study was to compare the results of once weekly and daily iron supplementation on hemoglobin (Hb), serum ferritin (SF) and physical growth among primary schoolchildren in southern Thailand."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"School, class, sex, age, ethnic group and socioeconomic status (parents&rsquo; education, father&rsquo;s and mother&rsquo;s occupations and family monthly income) data were collected via a questionnaire completed by parents before the intervention started. At baseline and the end of the study, weight and height were measured with subjects wearing school uniforms without belts and shoes and with empty pockets using a beam balance Detecto scale and stadiometer (Detecto Scales, Brooklyn, NY) to the nearest 0.1 kg and 0.5 cm, respectively.<br>
              <br> Before supplementation, well-trained nurses drew a 5-mL blood specimen from the cubital vein. A 2-mL portion of the blood was transferred to an EDTA-prepared tube and then stored in an ice box for subsequent Hb determination, blood morphology examination and screening for thalassemia. The remaining 3 mL of the blood was kept in a sealed plastic test tube at ambient temperature for SF assessment. Hb level was assessed with an automated machine (TechniconH*1E system, Tarrytown, NY) using the cyanmethemoglobin method (CV = 0.6&ndash;3.4%). The One Tube Osmotic Fragility Test combined with the Dichlorophenol Indophenol Precipitation Test was used to screen for potential thalassemic disease [<a href="#421743944163681429">1</a>]. Children with a positive One Tube Osmotic Fragility Test &lt; 85% or Dichlorophenol Ind-phenol Precipitation Test had further examination of blood cellmorphology by a hematologist and were excluded from the study if there was evidence of thalassemia or hemolytic diseases such as ovalocytosis...no attempt to exclude the thalassemia trait in this study. SF was assessed by the IMx assay (IMx Ferritin assay, Abbot Park, IL) using The Microparticle Enzyme Immunoassay method (CV = 4.4&ndash;6.4%). SF = 20 &micro;g/L was used to define anemia due to iron deficiency. At the end of intervention, a new 3-mL specimen of blood for Hb and SF testing was taken...Z-scores of weight-for-age and height-for-age were calculated using the National Center for Health Statistics growth references for weights and heights using the EPI INFO software, version 6 (Centers for Disease Control, Atlanta, GA)...<br>
              <br> All eligible children were given a single dose of 400 mg Albendazole at the beginning of the study and again 11 wk later to eliminate hookworm infection...<br>
              <br> IQ was measured by the Test of Nonverbal Intelligence, 2nd edition (TONI II, [<a href="#421744003011077270">2</a>]). TONI II is a standardized, objective, and culturally fair test measuring problem solving ability, a major aspect of intelligence. Its use was justified in this study because it measures the problem solving ability that we aimed to test (i.e., it is valid). Its correlation with the standard IQ test, WISC-R (Wechsler Intelligence Scale for Children-Revised), is 0.7 among Thai children (i.e., it is accurate) (Reungdaraganond, N., Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand, unpublished data)...Items are arranged in order of difficulty and each consists of 1 question-picture and 4 or 5 available responses but only 1 correct response. Each child began with the item indicated in the manual (depending on age) and continued until he/she made 3 incorrect responses in 5 consecutive items....School achievement was assessed by the school examination. There are 2 semesters in each Thai school year. The scores of the first and the second semester of Thai language and mathematics tests in the academic year 1998 and the scores of Thai language and mathematics tests in the second semester of the academic year 1999 were used for the pre- and postintervention measurements, respectively. School absence was recorded daily by the researcher who administered the supplementation."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>"...well-trained nurses drew a 5-mL blood specimen&hellip;further examination of blood cellmorphology by a hematologist&hellip;TONI II...Well-trained testers applied the test&hellip;School absence was recorded daily by the researcher who administered the supplementation."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>"All oral administrations were strictly observed by either the principal investigator or the research assistant on each school day"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>"...two (public) schools&hellip;located Ëœ35 km from the research center and had a mixture of Buddhist and Muslim students.</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>"Ferrous sulfate 300 mg tablets (60 mg elemental iron) (Government Pharmaceutical Organization, Bangkok, Thailand) were used ...</p>
            <p>Placebo tablets, produced by the Faculty of Pharmacy, Prince of Songkla University, Thailand, were similar in color, shape, size and taste to the iron tablet. The tablets were placed in bottles, which were labeled only with the subject&rsquo;s name...Each child received 2 bottles. The first was to be taken on Monday only. The second was to be taken for the remaining days of the week. The daily group had iron in all the bottles, whereas the once weekly group had iron in the Monday bottle and placebo in the rest. The placebo group had placebo tablets in all of the bottles...16 wk of intervention"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>"Those in the placebo group were eventually supplemented with the appropriate dose for an appropriate amount of time after the study ended."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"All oral administrations were strictly observed by either the principal investigator or the research assistant on each school day to ensure that the tablets were swallowed."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"93.8 and 93.5% children in the daily and weekly groups received iron tablets as planned...Six children (n = 1, 4 and 1 in the daily, weekly and placebo groups, respectively) moved to other schools out of the study site during the study period and were thus excluded from the analysis of outcome."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Shah 2002</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Effectiveness of weekly vs daily iron and folic acid supplementation for control of anemia in adolescent Nepalese girls. </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"Consecutive healthy adolescent girls"<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"The aim of this study was to investigate whether supervised weekly iron and folic acid supplementation would lower the prevalence of anemia and improve hematocrit status as effectively as daily supplementation in adolescent Nepalese girls, in whom baseline prevalence of anemia is suspected to be quite high."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Subjects who complained of abdominal pain and other gastrointestinal ad-verse effects were reassured about the harmless nature of the tablets."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"The girls were questioned and examined by B.K.S.; a detailed sociodemographic profile was obtained, including the parents&rsquo; education and occupation, type of housing, water supply, and toilet facilities. Type of diet (vegetarian or non-vegetarian), history of passage of worms, and menarchal status were recorded. Presence of pallor, icterus, edema,hyperpigmentation, lymphadenopathy, platynychia, bleeding spots, xerophthalmia, and goiter were recorded on a predesigned form.<br>
              <br> Physical examinations were conducted to rule out any systemic abnormalities. Weight, height, and mid-arm circumference were measured using standard techniques [<a href="#421721969812850650">3</a>]...The baseline hematocrit of each girl was estimated using the microhematocrit technique...Fifteen days after the end of the study period (100 days or14 weeks), the remaining subjects were reevaluated by measuring their hematocrit."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"The girls were questioned and examined by B.K.S...The drug was given to the parents on a weekly basis"<br> B.K.S is a MBBS and first author of this publication</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>individual </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"A Government Girl School in Dharan, Nepal,an urban foothill town that is 305 m above sea level." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Group A received supplementation with tablets containing 350 mg of ferrous sulfate and1.5 mg of folic acid once a day for 90 to 100 days...</p>
            <p>Group C served as a control and did not receive any medication."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Girls in the control group who were found to be anemic were offered therapy after the study was completed." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"A few girls whose symptoms persisted were asked to take the tablets after a meal. Those with severe persistent symptoms were asked to stop taking the drug."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"The drug was given to the parents on a weekly basis, and they were asked to maintain a record of its consumption."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"The number of dropouts due to noncompliance was 8 (11.4%), 4 (6%), and 4(5.6%), respectively, in the 3 groups." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Lambert 2002</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Effects of Iron Treatment on Cognitive Performance and Working Memory in Non-anaemic, Iron-deficient Girls</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"adolescent girls with iron deficiency"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"The aim of the study described below was to address the question of whether iron deficiency affects the cognitive performance of female school age adolescents."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>Experimental task materials; tablets</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"Participants completed the four experimental tasks in the following order: <i>Hopkins Verbal Learning Test</i> (HVLT), <i>Stroop Task</i>, <i>Visual Search</i>, <i>Reading Span Task</i>.</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>"researchers"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Verbally; laptop computer; tablets</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>"a high school in Auckland, New Zealand"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>"one tablet per day, preferably before breakfast"; "each tablet of Ferrogradumet (abbott) contained a daily dose equivalent to 105 mg of elemental iron. If a tablet was missed, two were to be taken on the next day."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>"At a debriefing meeting following completion of all the cognitive tests participants were informed of initial results from the study. Each participant received a letter informing them as to what treatment group they were in, and of their post-treatment ferritin and haemoglobin levels. Participants in the placebo group received an eight week supply of iron tablets after the trial, to ensure that they were not disatvantaged relative to the Iron group."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"The number of tablets taken during each week was recorded, as were any side effects that had occured."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"Five dropped out in the course of the trial, leaving 116 participants who completed the study."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Ermis 2002</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>"Effects of three different iron supplementations in term healthy infants after 5 months of life"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>infants "at 5 months of age" with "no gestational problem (hypertension, pre-eclampsia, ablatio placenta, infection), no congenital anomalies, no neonatal complications, no emergency cesarean section, no jaundice requiring phototherapy, no hospitalization, no chronic illness, no iron therapy, no formula feeding and having exclusive breastfeeding, birthweight &gt; 3.0 kg, gestational age &gt; 37 weeks."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"the efficacy and safety of iron supplementation and the lowest dose of iron that prevents IDA should be evaluated carefully. In this study, we investigated the effects of iron supplementation at doses of 1 mg/kg/day, 2 mg/kg/day and 2 mg/kg/every other day on hematological values of breastfed infants."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"We took two venous blood samples from infants at 5months of age on each morning before feeding, and repeated at 9 months. One of two blood samples was placed in an EDTA test tube and used to measure hemogram by cell counter analysis method (CoulterMicro Diff 18, Miami, USA). The other blood sample was placed in a clear test tube and was used to calculate serum ferritin (SF) level by the electro-chemiluminescence immunoassay (ECLIA) method(Hitachi Elecsys 2010, Tokyo, Japan)."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>"The supplement was given by the mother"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>administration by mother</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>"Research Hospital of Karaelmas University, Faculty of Medicine in Zonguldak, Turkey."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>"Iron supplementation was given at the doses of 1 mg/kg/day, 2 mg/kg/day and 2mg/kg/every other day to the subjects in group I (n1= 30); group II (n2= 30) and group III(n3 = 30), respectively, and the last group received placebo (n4= 23). Ferrous sulfate drops (Ferro-sanol: 1 mg~1drop, Adeka, Turkey) were used for iron supplementation... each morning, just before or after breastfeeding and at least 1 h before or after any other food intake."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"...the dosages were adjusted monthly according to infants&rsquo; weights"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"If the received iron drops were less than 75 per cent of the expected amount of the monthly time intervals, these cases were excluded from the study. For these reasons, two cases in group I, three cases in group II and one case in group III were excluded from the study. The causes of non-compliance were infection during iron usage, refusing iron drops due to unpleasant taste, or mothers forgetting to use iron drops."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Geltman 2001</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Daily Multivitamins with Iron to Prevent Anemia in Infancy: A Randomized Clinical Trial</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"healthy, full-term infants enrolled at their 6-month well-child visit"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"We therefore conducted a pilot study to assess the effectiveness of standard infant multivitamin drops with iron, compared to multivitamins without iron, as prophylaxis for reducing rates of anemia and iron deficiency without anemia during the first year of life in a nutritionally at-risk community."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>" The intervention group received standard, nonprescription infant multivitamin drops with iron."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>" The intervention group received standard, nonprescription infant multivitamin drops with iron. Each milliliter of the vitamins contained the following: elemental iron, 10 mg; vitamin A, 1,500 IU; vitamin C, 35 mg; vitamin D, 400 IU; vitamin E, 5 IU; thiamine, 0.5 mg; riboflavin, 0.6 mg; niacin, 8 mg; vitamin B6, 0.4 mg; and vitamin B12, 2 pg. The control group received the same multivitamins without iron. Parents were instructed to administer 1 mL of the multivitamins by mouth to their infants each day."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>"Parents were instructed to administer 1 mL of the multivitamins by mouth to their infants each day."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>drops; individual</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>"2 clinics, the Boston Medical Center Pediatric Primary Care Clinic (Boston, MA) and the Upham's Corner Health Center (Dorchester, MA)"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>"Combined with other dietary sources of iron, it was estimated that infants would receive approximately 2 mg/kg/day of elemental iron. Parents were supplied with 2 50 cc bottles of the multivitamins, an amount sufficient to cover the 3-month study period."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"Most parents did not return the vitamin bottles; therefore, measurement of adherence depended on parental report."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"our loss to follow-up was significant"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Domell&ouml;f 2001a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Iron supplementation of breast-fed Honduran and Swedish infants from 4 to 9 months of age"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>term, normal weight, exclusively breastfed infants in Sweden and Honduras at 4 months of age </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"However,  the effect of prophylactic iron supplemen-tation of healthy, term, breast-fed in-fants starting at 4 to 6 months of age isnot known. Because there are potential adverse  effects  of  iron  supplementation, the efficacy and safety of this approach should be evaluated  before large-scale  prevention  programs  for IDA are implemented. The aim of this randomized, double-blind, placebo-controlled trial was to investigate  the  effects  of  daily  iron supplementation to breast-fed infants on hemoglobin and other measures of iron status."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Between 4 and 6 months, the mothers were discouraged from giving anyother foods or fluids except for &ldquo;taste portions&rdquo; (&le;1 tablespoon per day) of foods with little or no iron&hellip;Between 6 and 9 months, the mothers continued breast-feeding  but  were  allowed  to give complementary food at their own discretion.  No  attempt  was  made  by the   investigators   to   influence   the choice of foods or the extent of breast-feeding." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Venous blood (~5 mL) was obtained at 4, 6, and 9 months of age. Part of the sample was collected in an EDTA test tube and immediately analyzed in duplicate for Hb (HemoCue, &Auml;ngelholm,Sweden) and ZPP (Protofluor Z, Helena  Labs,  Beaumont,  Tex).  These  2 devices were checked weekly against standard solutions at both sites. Erythrocyte  mean  cell  volume  was  measured  in  the  remainder  of  the  EDTA blood with automated blood counters in Honduras (Cell-Dyn 610, Abbot Di-agnostics, Berkshire, UK) and Sweden (Sysmex SE 9000, Tillquist, Sweden) .Part of the sample was collected in a lithium  heparin  tube  and,  after  centrifugation, plasma was stored frozen at&ndash;20&deg;C until analyzed for ferritin (Coat-A-Count  Ferritin  IRMA,  DiagnosticProducts  Corp,  Los  Angeles,  Calif), TfR (Ramco, Houston, Tex), and C-reactive protein (Nanorid, The BindingSite, Birmingham, England).<br>
              <br> Complementary   food   intake   between 6 and 9 months was estimated in Honduras by a bi-weekly 24-hour recall and a food frequency questionnaire  and  in  Sweden  by  a  monthly 5-day  food  diary.  Intakes  of  specific nutrients in Honduras were calculated with   the   FoodProcessor   program (ESHA  Research,  Salem,  Ore)  and in Sweden with the Food Composition Tables from the National Food Administration combined with information   from   Swedish   baby   food manufacturers.<br>
              <br> Birth weights were measured by the investigators  in  Honduras  and  excerpted from delivery charts in Sweden. From 4 to 9 months of age, infant weight was measured monthly by the investigators at both study sites."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"The supplement or placebo was given by the mother each morning" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>administration by mother</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"2 sites: San Pedro Sula, Honduras, and Ume&aring;, Sweden." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"The iron supplement was a commercially available formulation (Fer-In-Sol,Mead Johnson, Evansville, Ind) of ferrous sulfate containing 25 mg/mL of elemental iron. The placebo solution had similar appearance and taste...The supplement was given at a dose corresponding to 1.0 mg of elemental iron per kg per day... each morning, just before  or  after  breast-feeding  and  at least 1 hour before or after any other food intake...from 4 to 9 months" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"the dose was  adjusted  monthly  according  to weight" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Compliance with the intervention was based on the mother&rsquo;s daily checklist or the amount of fluid remaining in the bottles each month. When these indicated that the infant had been given the study drops &lt;75%of the days during either of the time intervals (4 to 6 months or 6 to 9months), we considered these cases as noncompliant." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"At 4 months of age, 263 infants were randomized into the 3 intervention groups. Remaining in the study were232 infants at 6 months and 214 at 9months...we found 24 noncompliers (16 in Honduras and 8 in Sweden)." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Dijkhuizen 2001</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Effects of iron and zinc supplementation in Indonesian infants on micronutrient status and growth" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"...infants, 4 mo of age" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"In this study the effects of supplementation of iron and zinc, alone or combined, on iron status, zinc status and growth in Indonesian infants is investigated. Micronutrient deficiencies are prevalent in infants in developing countries, and deficiencies often coexist; thus, combined supplementation is an attractive strategy. However, little is known about interactions between micronutrients."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>"Mothers were informed of the procedures and purpose of the study."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"...infants were assessed anthropometrically and a short history concerning socioeconomic status, dietary and lactation habits and the health of the mother and infant was taken...At the monthly follow-up, the infant was assessed anthropometrically, and a short history concerning health, diet and lactation and possible adverse effects was taken. After 6 mo of supplementation, in addition to the usual follow-up procedure, a blood sample was taken of the infant for biochemical assessment of nutritional status, as well as a stool sample to check for parasite infestation...<br>
              <br> Anthropometry included measurement of weight,height and mid-upper-arm circumference by trained anthropometrists using standard methods. In addition, knee-heel length was measured with a knemometer. Z-scores for weight and height [weight-for-age (WAZ) [<a href="#421744174875042969">4</a>], height-for-age (HAZ) and weight-for-height (WHZ)] were calculated with EPI-Info, Version 6.02, using WHO [World Health Organization]-recommended growth curves [<a href="#404935757088486107">5</a>]. Anthropometric measurements reflect long-term growth performance, whereas current growth activity may be assessed using plasma insulin-like growth factor 1 concentrations (IGF-1) [<a href="#421744037753283735">6</a>].<br>
              <br> A nonfasting 5-mL venous blood sample was taken from the infants. A closed tube heparanized vacuum system was used to avoid zinc contamination (Becton Dickinson, Leiden, The Netherlands).Blood samples were immediately stored at 4&deg;C to prevent microhemolysis and separated within 5 h. Aliquots of plasma were stored at 230&deg;C until analysis. Hemoglobin concentrations were measured by the standard cyanoblue method (Humalyzer, Wiesbaden, Germany). Plasma zinc concentrations were analyzed with flame atomic absorption spectrophotometry (Varian, Clayton South, Vic, Australia) using trace-element-free procedures, as described in a previous article [<a href="#421744174875042969">4</a>]. The coefficient of variation (10% duplicate analysis and pooled control samples) for zinc analyses was &lt; 5%. Ferritin and IGF-1 were measured using commercial ELISA-kits (IBL, Hamburg, Germany) according to the guidelines of the manufacturer. C-reactive protein (CRP) was measured using immunoturbidimetric techniques at the Northern IrelandCenter for Diet and Health, University of Ulster, Northern Ireland (Cobas Fara Analyzer; Roche Products, Welwyn, UK). The coefficient of variation for the ferritin, IGF-1 and CRP assays was &lt; 10%. Plasma CRP concentrations were analyzed to assess the occurrence of the acute phase reaction, which lowers plasma concentrations of zinc and raises plasma concentrations of ferritin [<a href="#421744398492263584">7</a>]. Stool samples were screened for the most commonly occurring parasites (hookworm,TrichurasandAscaris) by an experienced microscopist. Parasitological examination of stool samples revealed an infection rate of &lt; 5% and was not different among the groups; hence, intestinal parasite infestation was not considered a major factor in the outcome of the study."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Supplementation...was given 5 d/wk for 6 mo by trained village health volunteers." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"At recruitment, every subject received a personal bottle with a dosing syringe, labeled with the subject&rsquo;s  name, subject number, health volunteer&rsquo;s name and the date."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"...six adjacent villages...rural area of Bogor District, West Java, Indonesia" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Supplementation...was given 5 d/wk for 6 mo...syrup containing iron (10 mg/d), zinc (10 mg/d), iron + zinc (10 mg of each/d) or placebo. Supplements were made by a local pharmaceutical company (PT. Kenrose, Jakarta, Indonesia) in cooperation with United Nations Children&rsquo;s Fund, Jakarta."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"The bottles were monitored by the health volunteer who gave the supplement each day to prevent accidental intoxication or overdosing....Bottles  were weighed before emission, replaced every month with a new bottle and weighed again after return to estimate the dose given to the infant a sa measure of compliance." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Mean overall compliance (&plusmn; SD) was 86% (&plusmn; 16%) of the total intended dose and was similar for all groups (x2 analysis)." </p>
          </td>
        </tr>
      </table>
    </div>
    <div>
      <table>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>Zavaleta 2000</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Efficacy and acceptability of two iron supplementation schedules in adolescent school girls in Lima, Peru" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"adolescent girls, 12&ndash;18 y old, who met the following criteria: living in the community for at least 6 mo before the study, healthy, nuliparous, menstruating regularly in the last 3mo, had not taken any multivitamin-mineral supplement in the last6 mo and a hemoglobin (Hb &gt;80 g/L)"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"The effectiveness of daily iron supplementation programs has been questioned because of the low efficiency of health services and the lack of compliance of the target groups [<a href="#421743284875190995">8</a>]. The use of intermittent supplementation schedules has been suggested as a way in which to improve compliance by reducing side effects. Several studies conducted in anemic preschool and school-aged children have shown that the efficacy of an intermittent iron supplementation schedule is similar to that of daily dosing [<a href="#421743284875190995">8</a>]. This study aimed to assess the feasibility, efficacy and acceptability of reducing anemia in adolescent girls attending public school in Lima, Peru using daily or intermittent iron supplementation."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"At entry, general socioeconomic information, weight, height and midupper-arm circumference were recorded. At the beginning and end of the trial, a blood sample was obtained by venipuncture for analysis of Hb, serum ferritin (SF) and free erythrocyte protoporphyrin (FEP). Hb was analyzed by the cyanometahemoglobin method, SF by ELISA using human antiferritin and antiferritin peroxidase anti-bodies from DAKO, and FEP by a hematofluoremeter."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Supplements were administered...under the close supervision of a field worker who also recorded acceptability and side effects."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Supplements were administered daily at school, between meals, together with a sweetened flavored drink without ascorbic acid and under the close supervision of a field worker who also recorded acceptability and side effects."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"public secondary school in Villa El Salvador, a periurban shantytown in Lima, Peru" </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"1) 60 mg iron as ferrous sulfate daily from Monday to Friday;...3) placebo, from Monday to Friday...The supplements were given for 17 wk. All tablets had the same brick color and shape and were produced for this study by a local pharmaceutical company (Instituto Quimioterapico S.A Lima, Peru) and distributed in coded blister packages." </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>&mdash;<br>  
            </p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"To ensure participation, girls received counseling on the benefits of taking iron tablets and about the possibility of side effects."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td colspan="1" style="vertical-align: top;">
            <p>"Girls took 94% of the expected dose of 85 pills, and the median consumption was 80 tablets in the three groups." </p>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <p>
              <b>CRP</b>: C-reactive protein; <b>d</b>: day(s); <b>ECLIA</b>: electro-chemiluminescence immunoassay; <b>FEP</b>: free erythrocyte protoporphyrin; <b>HAZ</b>: height-for-age Z-scores; <b>Hb</b>: haemoglobin;<b> </b>IGF-1: insulin-like growth factor 1; <b>mo</b>: month(s); <b>SF</b>: serum ferritin; <b>WAZ</b>: weight-for-age Z-scores; <b>WHO</b>: World Health Organization; <b>WHZ</b>: weight-for-height Z-scores;<b> wk</b>, week(s), <b>y</b>: year(s).</p>
            <p>&mdash;: denotes not reported</p>
          </td>
        </tr>
      </table>
    </div>
    <h2>References</h2>
    <ol>
      <li id="421743944163681429">
        <span publication-type="book"><span person-group-type="author"><span><span>Nopparatana</span> <span>C</span></span>, <span><span>Fukumaki</span> <span>Y</span></span>, <span><span>Pornpatkul</span> <span>M</span></span></span>. <span>Thalassemia in the South of Thailand: Prenatal and Postnatal Diagnosis</span>. <span>Songkhla</span>: <span>Department of Pathology, Faculty of Medicine, Prince of Songkla University</span>, <span>1996</span>. </span>
      </li>
      <li id="421744003011077270">
        <span publication-type="book"><span person-group-type="author"><span><span>Brown</span> <span>L</span></span>, <span><span>Sherbenou</span> <span>RJ</span></span>, <span><span>Johnsen</span> <span>SK</span></span></span>. <span>Test of Nonverbal Intelligence: A language-free measure of cognitive ability</span>. 2nd edition. <span>Austin</span>: <span>Pro-ed</span>, <span>1990</span>. </span>
      </li>
      <li id="421721969812850650">
        <span publication-type="book"><span person-group-type="author"><span><span>Jelliffe</span> <span>DB</span></span></span>. <span>The assessment of the nutritional status of the community (with special reference to field surveys in developing regions of the world</span>. Vol. <span>53</span>. <span>World Health Organization</span>, <span>1966</span>. </span>
      </li>
      <li id="421744174875042969">
        <span publication-type="journal"><span person-group-type="author"><span><span>Dijkhuizen</span> <span>MA</span></span>, <span><span>Wieringa</span> <span>FT</span></span>, <span><span>West</span> <span>CE</span></span></span>. <span>Concurrent micronutrient deficiencies in lactating mothers and their infants in Indonesia</span>. <span>American Journal of Clinical Nutrition</span> <span>2001</span>;<span>73</span>(<span>4</span>):<span>786-91</span>. [DOI: <a href="https://doi.org/10.1093/ajcn/73.4.786">10.1093/ajcn/73.4.786</a>]</span>
      </li>
      <li id="404935757088486107">
        <span publication-type="other"><span person-group-type="author"><span>World Health Organization</span></span>. <span>Iron deficiency anaemia. Assessment, prevention, and control. A guide for programme managers</span>. <span>Geneva, Switzerland: World Health Organization,</span> <span>2001</span>.</span>
      </li>
      <li id="421744037753283735">
        <span publication-type="journal"><span person-group-type="author"><span><span>Devine</span> <span>A</span></span>, <span><span>Rosen</span> <span>C</span></span>, <span><span>Mohan</span> <span>S</span></span>, <span><span>Baylink</span> <span>D</span></span>, <span><span>Prince</span> <span>RL</span></span></span>. <span>Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor binding proteins in postmenopausal women</span>. <span>American Journal of Clinical Nutrition</span> <span>1998</span>;<span>68</span>(<span>1</span>):<span>200-6</span>. [DOI: <a href="https://doi.org/10.1093/ajcn/68.1.200">10.1093/ajcn/68.1.200</a>]</span>
      </li>
      <li id="421744398492263584">
        <span publication-type="journal"><span person-group-type="author"><span><span>Filteau</span> <span>SM</span></span>, <span><span>Tomkins</span> <span>AM</span></span></span>. <span>Micronutrients and tropical infections</span>. <span>Transactions of the Royal Society of Tropical Medicine and Hygiene</span> <span>1994</span>;<span>88</span>(<span>1</span>):<span>1-3</span>. [DOI: <a href="https://doi.org/10.1016/0035-9203(94)90480-4">10.1016/0035-9203(94)90480-4</a>] [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/8153982">8153982</a>]</span>
      </li>
      <li id="421743284875190995">
        <span publication-type="journal"><span person-group-type="author"><span><span>Schultink</span> <span>W</span></span>, <span><span>Gross</span> <span>R</span></span>, <span><span>Gliwitzki</span> <span>M</span></span>, <span><span>Karyadi</span> <span>D</span></span>, <span><span>Matulessi</span> <span>P</span></span></span>. <span>Effect of daily vs twice weekly iron supplementation in Indonesian preschool children with low iron status</span>. <span>American Journal of Clinical Nutrition</span> <span>1995</span>;<span>61</span>(<span>1</span>):<span>111-5</span>. [DOI: <a href="https://doi.org/10.1093/ajcn/61.1.111">10.1093/ajcn/61.1.111</a>]</span>
      </li>
    </ol>
  </body>
</html>
